Plain Language Summary: New treatments, including gene therapy and bioengineered clotting products, are changing the way hemophilia is managed by reducing treatment burden and improving quality of life. Researchers are also developing additional therapies and technologies that may further improve care. However, many people with hemophilia around the world still lack access to diagnosis and effective treatment. The article emphasizes the need to address barriers related to income, race, gender, age, and healthcare access so that all patients can benefit from these medical advances.
